» Articles » PMID: 36952376

A Survey of Open Questions in Adaptive Therapy: Bridging Mathematics and Clinical Translation

Overview
Journal Elife
Specialty Biology
Date 2023 Mar 23
PMID 36952376
Authors
Affiliations
Soon will be listed here.
Abstract

Adaptive therapy is a dynamic cancer treatment protocol that updates (or 'adapts') treatment decisions in anticipation of evolving tumor dynamics. This broad term encompasses many possible dynamic treatment protocols of patient-specific dose modulation or dose timing. Adaptive therapy maintains high levels of tumor burden to benefit from the competitive suppression of treatment-sensitive subpopulations on treatment-resistant subpopulations. This evolution-based approach to cancer treatment has been integrated into several ongoing or planned clinical trials, including treatment of metastatic castrate resistant prostate cancer, ovarian cancer, and BRAF-mutant melanoma. In the previous few decades, experimental and clinical investigation of adaptive therapy has progressed synergistically with mathematical and computational modeling. In this work, we discuss 11 open questions in cancer adaptive therapy mathematical modeling. The questions are split into three sections: (1) integrating the appropriate components into mathematical models (2) design and validation of dosing protocols, and (3) challenges and opportunities in clinical translation.

Citing Articles

Deciphering population-level response under spatial drug heterogeneity on microhabitat structures.

Hu Z, Wood K, Wood K bioRxiv. 2025; .

PMID: 40027692 PMC: 11870443. DOI: 10.1101/2025.02.13.638200.


Validation of polymorphic Gompertzian model of cancer through in vitro and in vivo data.

Soboleva A, Kaznatcheev A, Cavill R, Schneider K, Stankova K PLoS One. 2025; 20(1):e0310844.

PMID: 39787141 PMC: 11717199. DOI: 10.1371/journal.pone.0310844.


A mathematical framework for comparison of intermittent versus continuous adaptive chemotherapy dosing in cancer.

McGehee C, Mori Y NPJ Syst Biol Appl. 2024; 10(1):140.

PMID: 39614108 PMC: 11607384. DOI: 10.1038/s41540-024-00461-2.


Resistance Management for Cancer: Lessons from Farmers.

Seyedi S, Harris V, Kapsetaki S, Narayanan S, Saha D, Compton Z Cancer Res. 2024; 84(22):3715-3727.

PMID: 39356625 PMC: 11565176. DOI: 10.1158/0008-5472.CAN-23-3374.


The effect of tumor composition on the success of adaptive therapy: The case of metastatic Castrate-Resistant Prostate Cancer.

Salvioli M, Vandelaer L, Baena E, Schneider K, Cavill R, Stankova K PLoS One. 2024; 19(9):e0308173.

PMID: 39325718 PMC: 11426540. DOI: 10.1371/journal.pone.0308173.


References
1.
Hansen E, Read A . Cancer therapy: Attempt cure or manage drug resistance?. Evol Appl. 2020; 13(7):1660-1672. PMC: 7428817. DOI: 10.1111/eva.12994. View

2.
Piretto E, Delitala M, Ferraro M . Combination therapies and intra-tumoral competition: Insights from mathematical modeling. J Theor Biol. 2018; 446:149-159. DOI: 10.1016/j.jtbi.2018.03.014. View

3.
Greene J, Gevertz J, Sontag E . Mathematical Approach to Differentiate Spontaneous and Induced Evolution to Drug Resistance During Cancer Treatment. JCO Clin Cancer Inform. 2019; 3:1-20. PMC: 6873992. DOI: 10.1200/CCI.18.00087. View

4.
Cho H, Levy D . Modeling the chemotherapy-induced selection of drug-resistant traits during tumor growth. J Theor Biol. 2017; 436:120-134. DOI: 10.1016/j.jtbi.2017.10.005. View

5.
Fu X, Zhao Y, Lopez J, Rowan A, Au L, Fendler A . Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study. Nat Ecol Evol. 2021; 6(1):88-102. PMC: 8752443. DOI: 10.1038/s41559-021-01586-x. View